Early Initiation of Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: A Three-Year Clinical Experience (Q43826461)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 17, 2011

Language	Label	Description	Also known as
English	Early Initiation of Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: A Three-Year Clinical Experience	scientific article published on August 17, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Early Initiation of Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: A Three-Year Clinical Experience (English)

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

hyperparathyroidism

1 reference

based on heuristic

inferred from title

secondary hyperparathyroidism

1 reference

based on heuristic

inferred from title

hemodialysis patient

1 reference

based on heuristic

inferred from title

author name string

Leonardo Lucchi

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Chiara Carboni

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Lucia Stipo

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Vittoria Malaguti

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Federica Ferrari

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Romina Graziani

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Silvia Arletti

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Catia Graziosi

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21848793

9 December 2024

publication date

17 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1525-1594.2011.01270.x

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1525-1594.2011.01270.x/fullpdf

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

Artificial Organs

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1186-1193

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Metabolic bone disease in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Consistent control of mineral and bone disorder in incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Clinical experience with cinacalcet HCl.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Inter-method variability in PTH measurement: implication for the care of CKD patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1594.2011.01270.X

21 January 2018

Increased risk of hip fracture among patients with end-stage renal disease

4

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

5

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors

6

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study

8

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism

23

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis

26

1 reference

10.1111/J.1525-1594.2011.01270.X

https://api.crossref.org/works/10.1111/J.1525-1594.2011.01270.X

9 December 2024

Identifiers

10.1111/J.1525-1594.2011.01270.X

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43826461&oldid=2285392442"